Treatment difference in percentage LDL\C (95% credible period) differ from baseline, evolocumab 140?mg Q2W (A) or evolocumab 420?mg QM (B) in week 12 vs comparator in week 12 analyses
Treatment difference in percentage LDL\C (95% credible period) differ from baseline, evolocumab 140?mg Q2W (A) or evolocumab 420?mg QM (B) in week 12 vs comparator… Read More »Treatment difference in percentage LDL\C (95% credible period) differ from baseline, evolocumab 140?mg Q2W (A) or evolocumab 420?mg QM (B) in week 12 vs comparator in week 12 analyses